Rotavirus genotype diversity in Tanzania during Rotavirus vaccine implementation between 2013 and 2018.

Autor: Michael F; Ministry of Health, Immunization and Vaccine Development Program, Dodoma, Tanzania., Mirambo MM; Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. mmmirambo@gmail.com., Lyimo D; Ministry of Health, Immunization and Vaccine Development Program, Dodoma, Tanzania., Salehe A; Ministry of Health, Immunization and Vaccine Development Program, Zanzibar, Tanzania., Kyesi F; Ministry of Health, Immunization and Vaccine Development Program, Dodoma, Tanzania., Msanga DR; Department of Paediatrics and Child Health, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania., Mahamba D; Department of Pediatrics and Child Health, College of Health Sciences, University of Dodoma, P.O. Box 395, Dodoma, Tanzania., Nyawale H; Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania., Kwiyolecha E; Department of Paediatrics and Child Health, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania., Okamo B; Department of Biochemistry and Molecular Biology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania., Mwanyika PJ; Department of Pediatrics and Child Health, Mbeya Zonal Referral Hospital, P.O. Box 419, Mbeya, Tanzania., Maghina V; Department of Pediatrics and Child Health, Mbeya Zonal Referral Hospital, P.O. Box 419, Mbeya, Tanzania., Bendera E; Department of Pediatrics and Child Health, Muheza Designated District Hospital, Tanga, Tanzania., Salehe M; Department of Pediatrics and Child Health, Bombo Regional Referral Hospital, Tanga, Tanzania., Hokororo A; Department of Paediatrics and Child Health, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania., Mwipopo E; Department of Pediatrics and Child Health, Mwananyamala Regional Referral Hospital, Dar es Salaam, Tanzania., Khamis AC; Department of Pediatrics and Child Health, Temeke Regional Referral Hospital, Dar es Salaam, Tanzania., Nyaki H; Ministry of Health, Immunization and Vaccine Development Program, Dodoma, Tanzania., Magodi R; Ministry of Health, Immunization and Vaccine Development Program, Dodoma, Tanzania., Mujuni D; Ministry of Health, Immunization and Vaccine Development Program, Dodoma, Tanzania., Konje ET; Department of Epidemiology and Biostatistics, School of Public Health, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania., Katembo B; National Public Health Laboratory, Dar es Salaam, Tanzania., Wilillo R; World Health Organization, Country Office, Dar es Salaam, Tanzania., Mshana SE; Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Dec 08; Vol. 13 (1), pp. 21795. Date of Electronic Publication: 2023 Dec 08.
DOI: 10.1038/s41598-023-49350-4
Abstrakt: The study aims to determine Rotavirus genotypes between 2013 and 2018 during implementation of ROTARIX vaccine in Tanzania. The analysis of surveillance data obtained between 2013 and 2018 was done to determine circulating genotypes after introduction of Rotarix vaccine. From 2013 to 2018, a total of 10,557 samples were collected and screened for Rotavirus using an enzyme immunoassay. A significant decrease in Rotavirus positivity (29.3% to 17.8%) from 2013 to 2018 (OR 0.830, 95% CI 0.803-0.857, P < 0.001) was observed. A total of 766 randomly selected Rotavirus positive samples were genotyped. Between 2013 and 2018, a total of 18 Rotavirus genotypes were detected with G1P [8] being the most prevalent. The G1P [8] strain was found to decrease from 72.3% in 2015 to 13.5% in 2018 while the G9P [4] strain increased from 1 to 67.7% in the same years. G2P [4] was found to decrease from 59.7% in 2013 to 6.8% in 2018 while G3P [6] decreased from 11.2% in 2014 to 4.1% in 2018. The data has clearly demonstrated that ROTARIX vaccine has provided protection to varieties of the wild-type Rotavirus strains. Continuous surveillance is needed to monitor the circulation of Rotavirus strains during this era of vaccine implementation.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: